[Report: Vistaseal™ – Intraoperative bleeding]

Bisaillon R, Kouakou C, Nieminen J, Saidi R
Record ID 32018004176
Original Title: Avis: Vistaseal – Saignement peropératoire
Authors' objectives: At the request of the manufacturer, Johnson and Johnson Medical Companies, the Institut national d’excellence en santé et en services sociaux (INESSS) evaluated Vistaseal™ (human fibrin sealant) for its inscription on the Liste des produits du système du sang du Québec for the following indication: ”in adults for supportive treatment in surgery for improvement of hemostasis, and for suture support in vascular surgery, where standard techniques are insufficient”.
Authors' results and conclusions: RESULTS: (#1: POPULATIONAL DIMENSION): Multiple tools, techniques and products are used to manage surgical bleeding. Fibrin sealants are among the products used when conventional manual techniques are unsuitable, for example, because of the location of the bleeding, or are insufficient to achieve hemostasis. The types of surgery for which a fibrin sealant may be useful have not been circumscribed. Therefore, the target population for this product is potentially vast. Although several other products and techniques are available for the requested indication, the direct comparators for Vistaseal™ for this evaluation are the other fibrin sealants on the Liste des produits du système du sang du Québec, namely, Tisseel™ and Evicel™. Evicel™ is currently distributed as a source of thrombin but could potentially be withdrawn from the market by the end of the year. In a surgical setting, there is a health need for an effective and easy-to-use adjunctive hemostatic agent with a favourable safety profile for the managementof persistent bleeding despite the use of conventional techniques. In the current context, the needs to be met are limited. (#2: CLINICAL DIMENSION): The main efficacy and safety data for Vistaseal™ fibrin sealant come from 4 randomized controlled trials and a network meta-analysis. Although the overall evidence was considered to be of moderate quality, several biases were identified that limit the significance of the results. Efficacy • Vistaseal™ is effective in providing hemostasis in the context of vascular surgery, liver resection and soft tissue surgery compared to manual compression and Surgicel™. Safety • The safety profile of Vistaseal™ is considered satisfactory and comparable to that of the other fibrin sealants. (#3: EXPERT PERSPECTIVE): The experts believe that the positioning of the product as a hemostatic agent is not representative of the practice in Québec, where fibrin sealants are used mostly as tissue glues. They find the lack of data for evaluating the efficacy of Vistaseal™ in this context unfortunate. • The experts consulted also regret the lack of comparative data for evaluating the hemostatic efficacy of Vistaseal™ relative to other hemostatic agents with a similar application. However, they feel that the available studies are sufficient to demonstrate the efficacy of Vistaseal™ as a hemostatic agent.
Authors' recomendations: Most of the members of the Comité scientifique de l’évaluation des médicaments aux fins d’inscription who exercised their right to vote are of the opinion that the therapeutic value of Vistaseal™ fibrin sealant should not be recognized in adults as supportive treatment in surgery for improvement of hemostasis or as suture support in vascular surgery, where standard techniques are insufficient. (#1 ARGUMENTS FOR THE MAJORITY POSITION):  The members felt that the health need for hemostasis in surgery is adequately addressed.  In this context, the demonstration of the value of a therapeutic alternative must take into consideration the quality of the evidence for establishing the equivalence of efficacy and safety relative to those of the comparator products. However, most of the members found the evidence presented insufficient in several respects, including the following: 1. The clinical relevance of the primary efficacy endpoint: An interproduct comparison based on a hard endpoint would have been more appropriate, particularly in a singleblind design. An endpoint such as blood product transfusion utilization reported by type of surgery would have been possible; 2. The relevance of the direct comparator: A direct comparator such as a fibrin sealant would have been more informative for assessing therapeutic equivalence. Such comparators were available at the time of the clinical studies of Vistaseal; 3. The product’s composition: The uncertainty surrounding the comparability of fibrin sealants in the absence of a direct comparison is exacerbated by certain distinct characteristics of Vistaseal™, such as not containing any factor XIII or aprotinin. (#2 ARGUMENTS FOR THE MINORITY POSITION)  Some members felt that the available data support the non-inferiority of Vistaseal™ relative to the other fibrin sealants and that the reported limitations do not justify opposing its inclusion as a competitor. In light of the available data, INESSS considers that adding Vistaseal™ to the Liste des produits du système du sang du Québec as an adjuvant treatment in surgery in adults for supportive treatment in surgery for improvement of hemostasis, or for suture support in vascular surgery, where standard techniques are insufficient, would not constitute a fair and reasonable option.
Authors' methods: Literature data and data provided by the manufacturer were reviewed to evaluate the efficacy and safety of the human fibrin sealant Vistaseal™. Contextual and experiential data from an online survey and expert consultations are presented as well.
Project Status: Completed
Year Published: 2022
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Canada
Province: Quebec
MeSH Terms
  • Blood Loss, Surgical
  • Hemostasis, Surgical
  • Hemostatics
  • Fibrin Tissue Adhesive
  • Fibrin
Organisation Name: Institut national d'excellence en sante et en services sociaux
Contact Address: L'Institut national d'excellence en sante et en services sociaux (INESSS) , 2021, avenue Union, bureau 10.083, Montreal, Quebec, Canada, H3A 2S9;Tel: 1+514-873-2563, Fax: 1+514-873-1369
Contact Name: demande@inesss.qc.ca
Contact Email: demande@inesss.qc.ca
Copyright: L'Institut national d'excellence en sante et en services sociaux (INESSS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.